The findings from the PROSPERO study reveal that multiple hospitalizations, long-term disease duration, prior surgeries, and factors like corticosteroid use and total parenteral nutrition significantly increase the risk of gallstone disease in patients with Crohn disease.
The approval of Amneal Pharmaceuticals’ generic version of rifaximin 550 mg oral tablets is tentative due to the product’s involvement in litigation.
The American Gastroenterology Association (AGA) updated its clinical practice guidelines for managing hepatitis B reactivation (HBVr) in at-risk individuals, recommending antiviral prophylaxis for high- and moderate-risk patients.
The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach to now include the full spectrum of inflammatory bowel disease.
Children born in spring or summer with a specific gene variant may have a higher risk of celiac disease and lower levels of a key protein, according to a study, potentially helping future research on autoimmune diseases.
A study found that patients with COVID-19 may have a higher risk of developing new gastrointestinal (GI) disorders compared with matched controls, highlighting the need for further research on long-term GI effects post COVID-19 infection.
Nationwide norovirus cases have recently increased, followed by an FDA warning for consumers to avoid oysters contaminated in a recent outbreak.
A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral therapy, may help alleviate persistent digestive symptoms and improve quality of life for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD), alongside standard drug treatments.
Tiago Biachi, MD, PhD, highlighted the transformative role of personalized medicine in gastrointestinal (GI) cancer treatment through advances in next-generation sequencing and circulating tumor DNA, while emphasizing the importance of lifestyle factors in prevention and recurrence.
The tablets are indicated for treatment of adults with chronic idiopathic constipation, with further research needed to assess efficacy and safety in children.
A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.
Tiago Biachi, MD, PhD, discusses the challenges of treating gastrointestinal (GI) cancers, particularly the limited effectiveness of immunotherapy for "cold tumors" and the need to make them more responsive to immune treatments.
